Related Experiment Video
Updated: Jun 20, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
[Patent foramen ovale: "les liaisons dangereuses" between anatomy and genetics]
Nicoletta Botto1, Lamia Ait-Ali, Rosa Sicari
1Istituto di Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa. botto@ifc.cnr.it
Insights
Genetic screening for thrombotic mutations is crucial in young patients with patent foramen ovale (PFO) and ischemic events. Early identification aids in developing effective secondary prevention strategies for these individuals.
Area of Science:
- Cardiovascular Medicine
- Genetics
- Neurology
Background:
- Patent foramen ovale (PFO) is a potential risk factor for ischemic events, particularly in younger populations.
- Thrombotic mutations are increasingly recognized as contributors to cerebrovascular events.
Observation:
- Two young male patients, aged 24 and 17, presented with transient ischemic attacks (TIAs).
- Both patients were diagnosed with PFO.
- Genetic analysis revealed Factor V Leiden heterozygosity in one patient and prothrombin G20210A heterozygosity in the other.
Findings:
- Both patients were carriers of the MTHFR 677T genotype.
- Elevated plasma homocysteine levels (22.3 +/- 3.9 micromol/L) were observed in both patients.
- The combination of PFO and thrombotic mutations suggests a significant risk for ischemic events.
Implications:
- These findings underscore the importance of genetic screening for thrombotic mutations in young patients experiencing PFO-related ischemic events.
- Implementing genetic screening can enhance secondary prevention strategies.
- Personalized risk assessment and management are vital for preventing recurrent ischemic episodes in this demographic.
Abstract:
We reported a case of two 24-year-old and 17-year-old male patients with episode of transient ischemic attacks and diagnosed as having patent foramen ovale (PFO). One patient had heterozygosity for the factor V Leiden mutation, and one other had heterozygosity for prothrombin G20210A mutation. Both of them were also carriers for MTHFR 677T genotype with elevated plasma levels of homocysteine (22.3 +/- 3.9 micromol/L). These findings strongly confirm and emphasize the importance of the genetic screening for thrombotic mutations in young patients with PFO-related ischemic events in order to improve secondary prevention strategies.
More Related Videos
10:23Three-Dimensional Cephalometric Landmark Annotation Demonstration on Human Cone Beam Computed Tomography Scans
Published on: September 8, 2023
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Genetic Lingo
Incomplete Dominance
Pedigree Analysis
Sex Linked Disorders
Sutures of the Skull
Sutures are immobile joints between adjacent bones of the skull. The narrow gap between the bones is filled with dense, fibrous connective tissue that unites the bones. The long sutures located between the skull bones are not straight but instead follow irregular, tightly twisting paths. These twisting lines tightly...
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...